Substudy 02C
Stage/indication incl. Brief info
Melanoma - 1st line
Resectable stage IIIB-IIID
Neoadjuvant therapy
Anti-PD1 + anti-TIGIT vs Anti-PD1 + oncolytic virotherapy vs anti-PD1 + Subsequent adjuvant anti-PD1 therapy
Short title
Merck MK3475
Substudy 02C
(UmbrellaTrial)
NCT04303169
Official title
A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants With Melanoma: Substudy 02C